Home
EWTX
EWTX News

Latest Edgewise Therapeutics Inc. (EWTX) News on May 22, 2025

Does Edgewise Therapeutics (EWTX) Have the Potential to Rally 174.68% as Wall Street Analysts Expect?

Zacks

8 days ago

Does Edgewise Therapeutics (EWTX) Have the Potential to Rally 174.68% as Wall Street Analysts Expect?

Edgewise Therapeutics to Present at the RBC Capital Markets Global Healthcare Conference on May 20, 2025

PR Newswire

8 days ago

Edgewise Therapeutics to Present at the RBC Capital Markets Global Healthcare Conference on May 20, 2025

MT Newswires

13 days ago

RBC Trims Price Target on Edgewise Therapeutics to $48 From $52, Keeps Outperform, Speculative Risk

MT Newswires

14 days ago

Wedbush Adjusts Price Target on Edgewise Therapeutics to $40 From $43, Maintains Outperform Rating

MT Newswires

14 days ago

Edgewise Therapeutics' Q1 Net Loss Widens; Shares Down Over 3%

Edgewise Therapeutics Reports First Quarter 2025 Financial Results and Recent Business Highlights

PR Newswire

14 days ago

Edgewise Therapeutics Reports First Quarter 2025 Financial Results and Recent Business Highlights

Is Edgewise Therapeutics, Inc. (EWTX) the Best Small Cap Stock to Buy with the Biggest Upside Potential?

Insider Monkey

17 days ago

Is Edgewise Therapeutics, Inc. (EWTX) the Best Small Cap Stock to Buy with the Biggest Upside Potential?

Why Edgewise Therapeutics Stock Popped This Week

Motley Fool

20 days ago

Why Edgewise Therapeutics Stock Popped This Week

MT Newswires

22 days ago

Guggenheim Starts Edgewise Therapeutics With Buy Rating, $41 Price Target

Is Edgewise Therapeutics Inc. (NASDAQ:EWTX) the Most Promising Small-Cap Stock According to Analysts?

Insider Monkey

a month ago

Is Edgewise Therapeutics Inc. (NASDAQ:EWTX) the Most Promising Small-Cap Stock According to Analysts?

Bristol Myers stumbles in bid to widen heart drug’s use

BioPharma Dive

a month ago

Bristol Myers stumbles in bid to widen heart drug’s use

The Zacks Analyst Blog Highlights Pacira Biosciences, Edgewise, Sarepta Therapeutics, Amgen and Bristol Myers Squibb

Zacks

a month ago

The Zacks Analyst Blog Highlights Pacira Biosciences, Edgewise, Sarepta Therapeutics, Amgen and Bristol Myers Squibb

Biotech Stock Roundup: PCRX Up on Patent News, EWTX Down on Study Data & More

Zacks

a month ago

Biotech Stock Roundup: PCRX Up on Patent News, EWTX Down on Study Data & More

Edgewise Therapeutics, Inc. (EWTX): Among Stocks Insiders Bought in April After Trump’s Tariff Rollout

Insider Monkey

a month ago

Edgewise Therapeutics, Inc. (EWTX): Among Stocks Insiders Bought in April After Trump’s Tariff Rollout

EWTX Stock Down 48% in a Week Despite Upbeat Cardiomyopathy Study Data

Zacks

a month ago

EWTX Stock Down 48% in a Week Despite Upbeat Cardiomyopathy Study Data

Edgewise Therapeutics (EWTX): Among Unstoppable Stocks That Could Double Your Money

Insider Monkey

2 months ago

Edgewise Therapeutics (EWTX): Among Unstoppable Stocks That Could Double Your Money

Edgewise Therapeutics Downgraded Following Safety Issues in Heart Drug Trial

GuruFocus.com

2 months ago

Edgewise Therapeutics Downgraded Following Safety Issues in Heart Drug Trial

MT Newswires

2 months ago

Edgewise Therapeutics Says Believes Atrial Fibrillation Not Driven by EDG-7500 in Phase 2 Trial, RBC Says

MT Newswires

2 months ago

Wedbush Adjusts Edgewise Therapeutics Price Target to $43 From $45, Maintains Outperform Rating

MT Newswires

2 months ago

RBC Lowers Price Target on Edgewise Therapeutics to $52 From $56, Keeps Outperform, Speculative Risk

Why Edgewise Therapeutics And Cytokinetics Stocks Just Diverged

Investor's Business Daily

2 months ago

Why Edgewise Therapeutics And Cytokinetics Stocks Just Diverged

Edgewise Therapeutics Stock Plummets on Drug Trial 'Adverse Events'

Investopedia

2 months ago

Edgewise Therapeutics Stock Plummets on Drug Trial 'Adverse Events'

MT Newswires

2 months ago

Sector Update: Health Care Stocks Fall Pre-Bell Wednesday

MT Newswires

2 months ago

Edgewise Therapeutics Reports New Results From Phase 2 Hypertrophic Cardiomyopathy Trial

MT Newswires

2 months ago

Edgewise Therapeutics Prices $200 Million Offering

Edgewise Therapeutics Announces Pricing of $200 Million Underwritten Offering of Common Stock

PR Newswire

2 months ago

Edgewise Therapeutics Announces Pricing of $200 Million Underwritten Offering of Common Stock

Edgewise Therapeutics to Host Webcast Event to Discuss Top-Line Results from Phase 2 CIRRUS-HCM 28-Day Trial of EDG-7500 in Hypertrophic Cardiomyopathy (HCM) on Wednesday, April 2 at 8:30 am Eastern Time

PR Newswire

2 months ago

Edgewise Therapeutics to Host Webcast Event to Discuss Top-Line Results from Phase 2 CIRRUS-HCM 28-Day Trial of EDG-7500 in Hypertrophic Cardiomyopathy (HCM) on Wednesday, April 2 at 8:30 am Eastern Time

Edgewise Therapeutics to Present on Sevasemten for the Treatment of Becker Muscular Dystrophy at the 2025 MDA Clinical and Scientific Conference

Business Wire

2 months ago

Edgewise Therapeutics to Present on Sevasemten for the Treatment of Becker Muscular Dystrophy at the 2025 MDA Clinical and Scientific Conference

Edgewise Therapeutics to Present at the Leerink Partners Global Healthcare Conference on March 11, 2025

Business Wire

3 months ago

Edgewise Therapeutics to Present at the Leerink Partners Global Healthcare Conference on March 11, 2025

MT Newswires

3 months ago

Edgewise Therapeutics Reports Wider-Than-Expected Q4 Net Loss

Edgewise Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Business Highlights

Business Wire

3 months ago

Edgewise Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Business Highlights

Should You Invest in Edgewise Therapeutics (EWTX)?

Insider Monkey

3 months ago

Should You Invest in Edgewise Therapeutics (EWTX)?

MT Newswires

3 months ago

Edgewise Therapeutics Insider Sold Shares Worth $300,300, According to a Recent SEC Filing

MT Newswires

3 months ago

Edgewise Therapeutics Insider Sold Shares Worth $287,316, According to a Recent SEC Filing

MT Newswires

3 months ago

Edgewise Therapeutics Insider Sold Shares Worth $276,776, According to a Recent SEC Filing

Why Is Andreas Halvorsen Bullish On Edgewise Therapeutics, Inc. (EWTX) Now?

Insider Monkey

4 months ago

Why Is Andreas Halvorsen Bullish On Edgewise Therapeutics, Inc. (EWTX) Now?

MT Newswires

4 months ago

Edgewise Therapeutics Names Behrad Derakhshan as COO; Shares Fall

Edgewise Therapeutics Strengthens Leadership Team to Support Late-Stage Clinical Development

Business Wire

4 months ago

Edgewise Therapeutics Strengthens Leadership Team to Support Late-Stage Clinical Development

MT Newswires

4 months ago

Stifel Nicolaus Initiates Coverage on Edgewise Therapeutics With Hold Rating, $30 Price Target

Edgewise Therapeutics (NASDAQ:EWTX) Is In A Good Position To Deliver On Growth Plans

Simply Wall St.

4 months ago

Edgewise Therapeutics (NASDAQ:EWTX) Is In A Good Position To Deliver On Growth Plans

Edgewise Therapeutics Provides Corporate Update and Highlights Priorities for 2025

Business Wire

4 months ago

Edgewise Therapeutics Provides Corporate Update and Highlights Priorities for 2025

Edgewise Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference on January 13, 2025

Business Wire

4 months ago

Edgewise Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference on January 13, 2025

MT Newswires

5 months ago

Edgewise Therapeutics Insider Sold Shares Worth $2,737,470, According to a Recent SEC Filing

Biotech Stock Roundup: Updates From GILD, REGN, GSK, ANAB Down on Study Data, EWTX Gains

Zacks

5 months ago

Biotech Stock Roundup: Updates From GILD, REGN, GSK, ANAB Down on Study Data, EWTX Gains

EWTX Stock Rises on Upbeat Data From Rare Muscular Disorder Study

Zacks

5 months ago

EWTX Stock Rises on Upbeat Data From Rare Muscular Disorder Study

Edgewise Therapeutics' Lead Candidate Reduces Biomarker Levels In Mid-Stage Study In Patients With Muscle Weakness Disease

Benzinga

5 months ago

Edgewise Therapeutics' Lead Candidate Reduces Biomarker Levels In Mid-Stage Study In Patients With Muscle Weakness Disease

MT Newswires

5 months ago

Sector Update: Health Care Stocks Mixed Pre-Bell Monday

MT Newswires

5 months ago

Sector Update: Health Care

MT Newswires

5 months ago

Edgewise's Phase 2 Trial of Sevasemten to Treat Becker Muscular Dystrophy Meets Primary Endpoint; Shares Up 22% Pre-Bell

Edgewise weighs fast approval path for muscular dystrophy drug

BioPharma Dive

5 months ago

Edgewise weighs fast approval path for muscular dystrophy drug

Edgewise Therapeutics Announces Positive Topline Results from the CANYON Phase 2 Trial of Sevasemten in Individuals with Becker Muscular Dystrophy (Becker)

Business Wire

5 months ago

Edgewise Therapeutics Announces Positive Topline Results from the CANYON Phase 2 Trial of Sevasemten in Individuals with Becker Muscular Dystrophy (Becker)

MT Newswires

6 months ago

Edgewise Therapeutics Clarifies FDA Warning Unrelated to Clinical Trials, Data

Edgewise Provides Statement Regarding Company’s Relationship with Dr. Han Phan at Rare Disease Research

Business Wire

6 months ago

Edgewise Provides Statement Regarding Company’s Relationship with Dr. Han Phan at Rare Disease Research

MT Newswires

6 months ago

Truist Raises Price Target on Edgewise Therapeutics to $50 From $33, Keeps Buy Rating

Edgewise Therapeutics to Present at the Piper Sandler 36th Annual Healthcare Conference on December 3, 2024

Business Wire

6 months ago

Edgewise Therapeutics to Present at the Piper Sandler 36th Annual Healthcare Conference on December 3, 2024

MT Newswires

6 months ago

RBC Capital Adjusts Edgewise Therapeutics Price Target to $44 From $42, Maintains Outperform, Speculative Risk Rating

Edgewise Therapeutics Reports Third Quarter 2024 Financial Results and Recent Business Highlights

Business Wire

6 months ago

Edgewise Therapeutics Reports Third Quarter 2024 Financial Results and Recent Business Highlights

Edgewise Therapeutics, Inc. (EWTX): A Hot Stock to Buy Now

Insider Monkey

7 months ago

Edgewise Therapeutics, Inc. (EWTX): A Hot Stock to Buy Now

Edgewise Therapeutics to Present on Sevasemten (EDG-5506) for Becker Muscular Dystrophy (Becker) at the 29th International Annual Congress of the World Muscle Society

Business Wire

8 months ago

Edgewise Therapeutics to Present on Sevasemten (EDG-5506) for Becker Muscular Dystrophy (Becker) at the 29th International Annual Congress of the World Muscle Society

Novo sinks on obesity drug results; Sanofi reveals anticipated MS data

BioPharma Dive

8 months ago

Novo sinks on obesity drug results; Sanofi reveals anticipated MS data

MT Newswires

8 months ago

RBC Raises Price Target on Edgewise Therapeutics to $42 From $32, Keeps Outperform, Speculative Risk

Company News for Sep 20, 2024

Zacks

8 months ago

Company News for Sep 20, 2024

Edgewise’s EDG-7500 shows benefit in two obstructive HCM trials

Clinical Trials Arena

8 months ago

Edgewise’s EDG-7500 shows benefit in two obstructive HCM trials

How Edgewise, Up 55%, Is Hoping To Edge Out Bristol, Cytokinetics In Heart Disease

Investor's Business Daily

8 months ago

How Edgewise, Up 55%, Is Hoping To Edge Out Bristol, Cytokinetics In Heart Disease

MT Newswires

8 months ago

Leerink Partners Raises Edgewise Therapeutics' Price Target to $42 From $32, Outperform Rating Maintained

MT Newswires

8 months ago

Top Midday Gainers

Why Edgewise Therapeutics Stock Is Up 50% on Thursday

Motley Fool

8 months ago

Why Edgewise Therapeutics Stock Is Up 50% on Thursday

Edgewise Therapeutics to Host Webcast Event to Discuss Top-Line Data from Phase 1 trial in Healthy Subjects and Phase 2 CIRRUS-HCM Trial in Patients with Obstructive Hypertrophic Cardiomyopathy (HCM) on Thursday, September 19 at 8:30 am Eastern Time

Business Wire

8 months ago

Edgewise Therapeutics to Host Webcast Event to Discuss Top-Line Data from Phase 1 trial in Healthy Subjects and Phase 2 CIRRUS-HCM Trial in Patients with Obstructive Hypertrophic Cardiomyopathy (HCM) on Thursday, September 19 at 8:30 am Eastern Time

Here's Why We're Not Too Worried About Edgewise Therapeutics' (NASDAQ:EWTX) Cash Burn Situation

Simply Wall St.

9 months ago

Here's Why We're Not Too Worried About Edgewise Therapeutics' (NASDAQ:EWTX) Cash Burn Situation

Edgewise Therapeutics Reports Second Quarter 2024 Financial Results and Recent Business Highlights

Business Wire

9 months ago

Edgewise Therapeutics Reports Second Quarter 2024 Financial Results and Recent Business Highlights

‘Don’t Be Scared of Heights’: J.P. Morgan Suggests 2 Stocks to Buy

TipRanks

10 months ago

‘Don’t Be Scared of Heights’: J.P. Morgan Suggests 2 Stocks to Buy

Here's Why Edgewise Therapeutics, Inc. (EWTX) is a Great Momentum Stock to Buy

Zacks

10 months ago

Here's Why Edgewise Therapeutics, Inc. (EWTX) is a Great Momentum Stock to Buy

Three Surprising Names That Could Be On Biogen's Buyout Shortlist

Investor's Business Daily

10 months ago

Three Surprising Names That Could Be On Biogen's Buyout Shortlist

MT Newswires

10 months ago

Top Midday Gainers

MT Newswires

10 months ago

JPMorgan Raises Price Target on Edgewise Therapeutics to $30 From $27, Maintains Overweight Rating

GuruFocus.com

a year ago

Edgewise Therapeutics Inc (EWTX) Reports First Quarter 2024 Financial Results

Edgewise Therapeutics to Present at the RBC Capital Markets Global Healthcare Conference on May 15, 2024

Business Wire

a year ago

Edgewise Therapeutics to Present at the RBC Capital Markets Global Healthcare Conference on May 15, 2024

MT Newswires

a year ago

Wedbush Raises Edgewise Therapeutics' PT to $31 From $26, Keeps Outperform Rating

Edgewise Therapeutics Reports First Quarter 2024 Financial Results and Recent Business Highlights

Business Wire

a year ago

Edgewise Therapeutics Reports First Quarter 2024 Financial Results and Recent Business Highlights

Edgewise Therapeutics Appoints Arlene Morris to its Board of Directors

Business Wire

a year ago

Edgewise Therapeutics Appoints Arlene Morris to its Board of Directors

Edgewise Therapeutics doses first subject in HCM drug trial

Clinical Trials Arena

a year ago

Edgewise Therapeutics doses first subject in HCM drug trial

MT Newswires

a year ago

Edgewise Therapeutics Says First Patient Dosed in Phase 2 Hypertrophic Cardiomyopathy Trial

Edgewise Therapeutics Doses First Patient in Phase 2 CIRRUS-HCM Trial of EDG-7500 in Obstructive Hypertrophic Cardiomyopathy (HCM)

Business Wire

a year ago

Edgewise Therapeutics Doses First Patient in Phase 2 CIRRUS-HCM Trial of EDG-7500 in Obstructive Hypertrophic Cardiomyopathy (HCM)

MT Newswires

a year ago

Edgewise Therapeutics Secures Orphan Drug Designations for Sevasemten in EU

Edgewise Receives European Medicines Agency (EMA) Orphan Drug Designations for Sevasemten (EDG-5506) for the Treatment of Becker and Duchenne Muscular Dystrophies

Business Wire

a year ago

Edgewise Receives European Medicines Agency (EMA) Orphan Drug Designations for Sevasemten (EDG-5506) for the Treatment of Becker and Duchenne Muscular Dystrophies

Edgewise Therapeutics Announces Positive Two-Year Topline Results from the ARCH Open Label Trial of Sevasemten (EDG-5506) in Adults with Becker Muscular Dystrophy (Becker)

Business Wire

a year ago

Edgewise Therapeutics Announces Positive Two-Year Topline Results from the ARCH Open Label Trial of Sevasemten (EDG-5506) in Adults with Becker Muscular Dystrophy (Becker)

Edgewise Therapeutics Announces Upcoming Podium Presentation at the American College of Cardiology's 2024 Annual Scientific Session

Business Wire

a year ago

Edgewise Therapeutics Announces Upcoming Podium Presentation at the American College of Cardiology's 2024 Annual Scientific Session

Edgewise Therapeutics to Present at the Cantor Virtual Muscular Dystrophy Symposium on April 2, 2024

Business Wire

a year ago

Edgewise Therapeutics to Present at the Cantor Virtual Muscular Dystrophy Symposium on April 2, 2024

Edgewise Therapeutics to Present at the Leerink Partners Global Biopharma Conference on March 11, 2024

Business Wire

a year ago

Edgewise Therapeutics to Present at the Leerink Partners Global Biopharma Conference on March 11, 2024

Edgewise Therapeutics to Present on EDG-5506 for the Treatment of Becker Muscular Dystrophy at the 2024 MDA Clinical and Scientific Conference

Business Wire

a year ago

Edgewise Therapeutics to Present on EDG-5506 for the Treatment of Becker Muscular Dystrophy at the 2024 MDA Clinical and Scientific Conference

Wall Street Analysts Predict a 52.78% Upside in Edgewise Therapeutics, Inc. (EWTX): Here's What You Should Know

Zacks

a year ago

Wall Street Analysts Predict a 52.78% Upside in Edgewise Therapeutics, Inc. (EWTX): Here's What You Should Know

Edgewise Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Business Highlights

Business Wire

a year ago

Edgewise Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Business Highlights

13 Best Booming Stocks to Buy Right Now

Insider Monkey

a year ago

13 Best Booming Stocks to Buy Right Now

Edgewise Receives U.S. FDA Fast Track Designation for EDG-5506 for the Treatment of Duchenne Muscular Dystrophy (Duchenne)

Business Wire

a year ago

Edgewise Receives U.S. FDA Fast Track Designation for EDG-5506 for the Treatment of Duchenne Muscular Dystrophy (Duchenne)

Insider Favorites: 7 Stocks with Bullish Buying Signals

InvestorPlace

a year ago

Insider Favorites: 7 Stocks with Bullish Buying Signals

Wall Street Analysts See a 33.27% Upside in Edgewise Therapeutics, Inc. (EWTX): Can the Stock Really Move This High?

Zacks

a year ago

Wall Street Analysts See a 33.27% Upside in Edgewise Therapeutics, Inc. (EWTX): Can the Stock Really Move This High?

Reasons to Invest in Collegium Pharmaceutical (COLL)

Insider Monkey

a year ago

Reasons to Invest in Collegium Pharmaceutical (COLL)

SRH Total Return Fund, Inc. Section 19(a) Notice

ACCESSWIRE

a year ago

SRH Total Return Fund, Inc. Section 19(a) Notice

Director ZERBE ROBERT L MD Sells Shares of Vericel Corp (VCEL)

GuruFocus.com

a year ago

Director ZERBE ROBERT L MD Sells Shares of Vericel Corp (VCEL)

These Stocks Are Moving the Most Today: SoFi, iRobot, McGrath RentCorp, ZoomInfo, Microsoft, Apple, and More

Barrons.com

a year ago

These Stocks Are Moving the Most Today: SoFi, iRobot, McGrath RentCorp, ZoomInfo, Microsoft, Apple, and More

Share on Social Networks: